FDA Proposes Direct Contracting Model with Venture Capital Firms to Accelerate Healthcare Innovation
核心洞察
The FDA issued a request for information on December 17, 2025, proposing a new contracting approach called "Foundational Innovation and RAPID Engagement" (FIRE) that would establish direct relationships with qualified venture capital firms.
Under the FIRE model, portfolio companies of approved VC firms would serve as subcontractors to provide biotechnology (搜索), medical devices (搜索), AI, and regulatory technology (搜索) solutions directly to the FDA.
The initiative aims to reduce reliance on traditional federal contractors and eliminate barriers that prevent early-stage innovators from engaging with the agency.
The U.S. Food and Drug Administration has unveiled a groundbreaking proposal that could fundamentally reshape how the agency engages with venture-backed healthcare innovation. On December 17, 2025, the FDA issued a request for information outlining a novel contracting approach designed to create direct pathways between the agency and innovative startups developing biotechnology (搜索), medical devices (搜索), artificial intelligence (搜索), and regulatory technology (搜索) solutions.
FIRE Model Introduces Direct VC-FDA Partnerships
The proposed "Foundational Innovation and RAPID Engagement" (FIRE) contracting model would establish direct contractual relationships between the FDA and qualified venture capital firms. Under this framework, portfolio companies within approved VC firms would serve as subcontractors, competing for and receiving task orders to provide products and services directly to the FDA.
The FDA's 19-question request for information seeks input on the feasibility, structure, and requirements for this unprecedented model. Key areas of inquiry include barriers that VC-backed startups face in federal contracting, qualification and compliance expectations, and methods to maintain competition while avoiding exclusion of innovative small businesses not represented in selected VC portfolios.
Addressing Current Procurement Limitations
The initiative directly responds to acknowledged limitations in existing federal contracting mechanisms. The FDA cited concerns that current systems often favor large systems integrators and labor-based vendors, creating accessibility challenges and potential misuse of small business set-aside programs. These barriers have historically discouraged scalable, product-driven solutions and created significant obstacles for early-stage innovators seeking to work with federal agencies.
The proposed FIRE model aims to reduce the agency's reliance on traditional "pass-through" intermediaries and eliminate procurement friction that has historically limited engagement with technology startups. By creating direct relationships with venture capital firms, the FDA seeks to tap into a broader range of innovative capabilities across biotechnology (搜索), medical devices (搜索), AI applications, and regulatory technology (搜索).
Broad Scope for Healthcare Innovation
The FIRE framework is designed to support a comprehensive range of FDA needs, including research initiatives, technology deployment, and regulatory innovation projects. This broad scope could potentially open new avenues for venture-backed companies developing cutting-edge healthcare solutions to contribute directly to the agency's mission of protecting and promoting public health.
The model introduces procurement-specific considerations that most venture funds and early-stage companies do not routinely manage, including organizational conflicts of interest, procurement integrity restrictions, intellectual property and data rights, flow-down compliance requirements, and contractor responsibility certifications.
Industry Response and Timeline
The FDA is requesting detailed feedback on qualification criteria, financial and administrative considerations, intellectual property protections, and regulatory compliance frameworks. Venture capital firms and their portfolio companies have until 2:00 p.m. ET on January 18, 2026, to submit responses to the comprehensive RFI.
This timeline provides the venture capital ecosystem with approximately one month to evaluate the proposal and provide input that could shape the final structure of the FIRE model. The response period represents a critical opportunity for life sciences investors and innovative companies to influence how the FDA engages with venture-backed innovation moving forward.
Implications for Healthcare Technology Development
If implemented, the FIRE model could create a meaningful new pathway for venture-backed healthcare innovation by establishing direct contractual relationships that bypass traditional procurement intermediaries. This approach could accelerate the integration of cutting-edge technologies into FDA operations while providing startups with unprecedented access to federal contracting opportunities.
The proposal reflects the FDA's recognition that traditional procurement approaches may not be optimally suited for engaging with the rapidly evolving landscape of healthcare technology innovation, particularly in areas such as artificial intelligence (搜索), advanced medical devices (搜索), and biotechnology (搜索) solutions where venture-backed companies often lead development efforts.